Lipin deficiency impairs diurnal metabolic fuel switching.

Lipin deficiency impairs diurnal metabolic fuel switching. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Lipin deficiency impairs diurnal metabolic fuel switching. Abstract Text:

Jun Xu,W N Paul Lee,Jack Phan,Mohammed F Saad,Karen Reue,Irwin J Kurland,

Fatty liver is a common feature of both obesity and lipodystrophy, reflecting compromised adipose tissue function. The lipin-deficient fatty liver dystrophy (fld) mouse is an exception, as there is lipodystrophy without a fatty liver. Using a combination of indirect calorimetry and stable-isotope flux phenotyping, we determined that fld mice exhibit abnormal fuel utilization throughout the diurnal cycle, with increased glucose oxidation near the end of the fasting period and increased fatty acid oxidation during the feeding period. The mechanisms underlying these alterations include a twofold increase compared with wild-type mice in tissue glycogen storage during the fed state, a 40% reduction in hepatic glucose production in the fasted state, and a 27-fold increase in de novo fatty acid synthesis in liver during the fed state. Thus, the inability to store energy in adipose tissue in the fld mouse leads to a compensatory increase in glycogen storage for use during the fasting period and reliance upon hepatic fatty acid synthesis to provide fuel for peripheral tissues during the fed state. The increase in hepatic fatty acid synthesis and peripheral utilization provides a potential mechanism to ameliorate fatty liver in the fld that would otherwise occur as a consequence of adipose tissue dysfunction.

Lipin deficiency impairs diurnal metabolic fuel switching. Publishing Authors By Initials

J Xu,WN Lee,J Phan,MF Saad,K Reue,IJ Kurland,

For similar proteins: nuclear proteins research abstracts see: proteins: nuclear proteins research

PUBMED ID PMID:

MEDLINE DATE:

Lipin deficiency impairs diurnal metabolic fuel switching. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Diabetes

VOLUME: 55

Page Numbers: 3429-38

Journal Abbreviation: Diabetes

ISSN: 0012-1797

DAY: 3

MONTH: Dec

YEAR: 2006

Lipin deficiency impairs diurnal metabolic fuel switching. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 372763

Lipin deficiency impairs diurnal metabolic fuel switching. Keywords Mesh Terms:

KEYWORDS: Nuclear Proteins

MESH TERMS: genetics

Chemical & Substance for Abstract: Lipin deficiency impairs diurnal metabolic fuel switching. Information

Substance Name: Fatty Acid Synthetase Complex

Registry Number: EC 6.-

Grant and Affiliation Information for Lipin deficiency impairs diurnal metabolic fuel switching.

AFFILIATION: State University of New York at Stony Brook, HSC T-15 Room 060, Stony Brook, NY 11794-8154, USA.

Country: United States

AGENCY: United States NHLBI

GRANT: HL28481

ACRONYM: HL

MEDLINETA: Diabetes

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Lipin deficiency impairs diurnal metabolic fuel switching Related Publications

• Alzheimer's disease and cumulative exposure to anesthesia: a case-control study.
• Amyotrophic lateral sclerosis among Guamanians in California.
• Decreased hepatic futile cycling compensates for increased glucose disposal in the Pten heterodeficient mouse.
• Descriptive epidemiology of primary intracranial neoplasms.
• Descriptive epidemiology of selected neurologic and myopathic disorders with particular reference to a survey in Rochester, Minnesota.
• Lipin deficiency impairs diurnal metabolic fuel switching.
• Malignant insulinoma: a rare presentation of a rare tumor.
• Osteonectin/SPARC polymorphisms in Caucasian men with idiopathic osteoporosis.
• Patterns and predictors of institutionalization in community-based dementia patients.
• Presentation of multiple sclerosis and other neurological studies in North America and the Western Pacific Islands.
• Survey procedures, definitions and sampling problems.
• The ability of the cat to withstand repeated electrically induced convulsions.
• Treatment of recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan: a phase II trial of the Puget Sound Oncology Consortium.